What Are Wall Street Analysts' Target Price for Henry Schein Stock?

Henry Schein, Inc. (HSIC), headquartered in Melville, New York, provides health care products and services to dental practitioners, laboratories, physician practices, and ambulatory surgery centers, government, institutional health care clinics, and other alternate care clinics. Valued at $9.9 billion by market cap, the company provides shop supplies, as well as dental and medical solutions and services to improve operational success and clinical outcomes.

Shares of this world’s largest health care solutions provider have outperformed the broader market over the past year. HSIC has gained 30.7% over this time frame, while the broader S&P 500 Index ($SPX) has rallied nearly 20.2%. In 2026, HSIC stock is up 18.1%, surpassing the SPX’s 12.6% rise on a YTD basis. 

Narrowing the focus, HSIC’s underperformance is apparent compared to the State Street SPDR S&P Health Care Services ETF (XHS). The exchange-traded fund has gained about 40.5% over the past year. Moreover, the ETF’s 26.6% gains on a YTD basis outshine the stock’s returns over the same time frame.

HSIC’s mixed performance was driven by strong internal sales and dental merchandise gains, offset by shrinking profitability and softer U.S. dental demand. CEO Frederick Lowery cited success converting occasional buyers into engaged customers, share gains in the U.S. and Canada, and growth in the Henry Schein One platform, which now has about 13,000 Dentrix Ascend subscribers. AI features and own-brand/specialty products, including implants and S.I.N. 360 drove higher revenue per user and margin. Management reaffirmed value-creation targets of over $200 million in operating income via outsourcing, procurement, and pricing, and updated guidance reflects continued tech and portfolio investments despite near-term U.S. headwinds.

On Aug. 4, HSIC shares rose over 3% after reporting its Q2 results. Its adjusted EPS of $1.27 exceeded Wall Street expectations of $1.22. The company’s revenue was $3.5 billion, exceeding Wall Street forecasts of $3.4 billion. HSIC expects full-year adjusted EPS in the range of $5.29 to $5.39.

For the current fiscal year, ending in December, analysts expect HSIC’s EPS to grow 7.7% to $5.35 on a diluted basis. The company’s earnings surprise history is impressive. It beat the consensus estimate in each of the last four quarters.

Among the 18 analysts covering HSIC stock, the consensus is a “Moderate Buy.” That’s based on nine “Strong Buy” ratings, eight “Holds,” and one “Strong Sell.” 

This configuration is more bullish than three months ago, with eight analysts suggesting a “Strong Buy.”

On Aug. 6, John Stansel from JPMorgan Chase & Co. (JPM) maintained a “Buy” rating on HSIC, with a price target of $102, implying a potential upside of 14.2% from current levels.

The mean price target of $97.06 represents an 8.7% premium to HSIC’s current price levels. The Street-high price target of $112 suggests a notable upside potential of 25.4%.